(redirected from thiazolidinedione)
Also found in: Dictionary, Medical, Wikipedia.
Related to thiazolidinedione: Alpha-glucosidase inhibitor, DPP-4 inhibitor
TZDThiazolidinedione (class of diabetes drugs)
TZDTime Zone Designator
TZDTurbo Zone Direct
TZDTowards Zero Deaths (highway safety initiative; Minnesota)
TZDTotal Zenith Delay
TZDThe Zombie Diaries (UK film)
TZDTamburaši Za Dušu
References in periodicals archive ?
Randomized clinical trial assessing the efficacy and safety of bromocriptine-qr when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus.
Thiazolidinedione use, fluid retention, and congestive heart failure a consensus statement from the american heart association and american diabetes association.
Add a second oral agent (such as a sulfonylurea, thiazolidinedione, sodium-glucose cotransporter-2 inhibitor, or dipeptidyl peptidase 4 inhibitor), a glucagon-like peptide-1 (GLP-1) receptor agonist, or basal insulin if metformin at a maximum tolerated dose does not achieve the HbA1c target over 3 months.
The effect of pioglitazone, ciglitazone and englitazone (members of insulin-sensitizing thiazolidinedione derivatives) on 3T3 cells (Szalkowski et al.
A retrospective study of nearly 15,000 adults aged 55 years and older who started on single-agent drug therapy for type 2 diabetes between 1999 and 2001 showed that 5 years after starting therapy, patients who started on metformin had a 23% lower 5-year risk for dementia, compared with patients who started on a thiazolidinedione (TZD) such as rosiglitazone (Avandia), reported Rachel Whitmer, Ph.
Researchers from the Perelman School of Medicine at the University of Pennsylvania found that patients taking thiazolidinedione (TZDs) drugs - which account for up to 20 percent of the drugs prescribed to diabetics in the United States-are two to three times more likely to develop bladder cancer than those who took a sulfonylurea drug, another common class of medications for diabetes.
A fracture risk was also seen among men who had been treated with thiazolidinedione (TZD) drugs--either rosiglitazone (Avandia, already linked with an increased risk of heart attack) or pioglitazone (Actos)--plus a loop diuretic.
INVESTIGATORS, looking into earlier findings that suggested a connection between antioxidants, thiazolidinedione (TZD) medications, and improvements in nonalcoholic steatohepatitis (NASH), conducted a multicenter double-blind trial enrolling 247 nondiabetic patients.
Research presented at the American Diabetes Association scientific sessions in June 2009 points to increased risk of fracture for people with type 2 diabetes who take a thiazolidinedione (TZD) such as pioglitazone (Actos) and rosiglitazone (Avandia) to help control their blood sugar.
We then demonstrate that: i) RORalpha, and specifically its RORalpha1 isoform, is expressed in DU 145 cells; ii) activation of RORalpha, by means of the thiazolidinedione derivative CGP 52,608 (the synthetic RORalpha activator), significantly reduces 5-LOX expression, both at mRNA (as evaluated by comparative RT-PCR) and at protein (as investigated by Western blot analysis) level (this was confirmed by the reduced activity of 5-LOX in CGP 52,608 treated cells); and iii) the treatment of DU 145 cells with CGP 52,608 completely abrogated the proliferative action of both LA and AA.
New York--Treatment with a thiazolidinedione, either pioglitazone or rosiglitazone, was linked to an increased rate of bone fractures, particularly in women, in several recently published reports.